2005, Número 2
<< Anterior Siguiente >>
Gac Med Mex 2005; 141 (2)
Mujer de 43 años de edad con deterioro funcional, disnea de reposo y dolor transfictivo de hemitórax derecho
Martínez GL, Arriaga-Nava R, Espinosa-Poblano E, Cruz-Alonso B, Halabe-Cherem J
Idioma: Español
Referencias bibliográficas: 20
Paginas: 149-154
Archivo PDF: 86.16 Kb.
FRAGMENTO
Mujer de 43 años de edad con disnea de reposo y dolor transfictivo de una semana de inicio. Además con fatiga, astenia, adinamia, disnea de medianos esfuerzos y tos con expectoración blanquecina de dos meses de evolución.
REFERENCIAS (EN ESTE ARTÍCULO)
Terence W, Hassouna H. Hypercoagulable states. Hematol Oncol Clin N Am 2000;14(2):355-377.
2. Bradbury AW, Mackenzie RK, Burns P, et al. Thrombophilia and Chronic Venous Ulceration, Eur J. Vasc Endovasc Surg 2002;24:97-104.
3. Iskander G, Cheng Y. Fundamentals of normal hemostasis. Ann Clin N Am 1999;17(4):715-731.
4. Hellman M. Thrombophilias: an overview. Prim Care Update Ob/Gyns 2002;9(6):226-230.
5. López-Baret P, Piuto JM, Romero A. Systematic Study of occult pulmonary thromboembolism in patients with deep venous thrombosis. J Vasc Surg 2001;33:515-521.
6. Mackinzie RK, Ludlam CA, Ruckley CV. The prevalence of thrombophilia in patients with chronic venous leg ulceration. J.Vasc Surg 2002;35:718-722.
7. Derksen RHWM, Groot PG. Tests for lupus anticoagulant revisited. Thromb Research 2004; article in press: 1-7
8. Goldhaber SZ. Pulmonary Embolism. Lancet 2004;363:1295-1305.
9. Wilson W. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin 2001;27(3):499-505.
Burns PJ, Mosquera DA, Bradbury AW. Prevalence and significance of thrombophilia in Peripheral Arterial Disease. Eur J. Vasc Endovasc Surg 2001;22:98-106.
Gali M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients risk? Thromb Research 2004; article in press: 1-5
Wisloff F, Jacobsen E, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Research 2003;108:263-271.
Crowther MA, Wisloff F. Evidence based treatment of antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Research 2004; article in press: 1-5
Crowther MA, Ginsberg JS, Gent M, et al. A randomized trial of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies. N Engl J Med 2003;349:1133-1138.
Finazzi G, Marchioli R, Barbui T. A randomized clinical trail of oral anticoagulant therapy in patients with antiphospholipid antibody syndrome: the WAPS study. J.Thromb Haemost 2003;1(51):OC365.
Hurlem M, Abdelnoor M, Smith P, et al. Al. Warfarin, aspirin or both after myocardial infarction. N.Engl J Med 2002;347(13):969-974.
Crowther MA. Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome. Thromb Research 2004; article in press: 1-4
Wilson WA, Gharavia AE, Koike T, et al. International Consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42(7):1309-1311
Levin SR, Brey RL, Tilley BC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-584.
Ando M, Takamoto S, Okita Y, et al. Operation for Chronic Pulmonary Thromboembolism Accompanied by Thrombophilia in 8 patients. Ann Thorac Surg 1998;66:1919-1924.